Oculis Holding AG

22.64
0.00 (0.00%)
Jan 22, 2025, 3:48 PM - Market open
0.00%
Bid 22.61
Market Cap 922.47M
Revenue (ttm) 699.61K
Net Income (ttm) -74.70M
EPS (ttm) -1.81
PE Ratio (ttm) -12.51
Forward PE -6.69
Analyst Buy
Ask 22.72
Volume 62,311
Avg. Volume (20D) 68,541
Open 22.88
Previous Close 22.64
Day's Range 22.61 - 23.00
52-Week Range 10.55 - 23.08
Beta 0.01

About OCS

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye ...

Industry Biotechnology
Sector Healthcare
IPO Date May 18, 2021
Employees 36
Stock Exchange NASDAQ
Ticker Symbol OCS

Analyst Forecast

According to 5 analyst ratings, the average rating for OCS stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 28.09% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Oculis Holding AG is scheduled to release its earnings on Mar 17, 2025, before market opens.
Analysts project revenue of $243.36K, reflecting a 16.64% YoY growth and earnings per share of -0.38, making a 0.00% YoY.
3 months ago
+18.1%
Oculis shares are trading higher after the company... Unlock content with Pro Subscription
4 months ago
+0.51%
Oculis Holding shares are trading higher after the company reported Q2 financial results.